Table 1.
Clinical trials targeting B7-H3 on solid tumors with multiple effector mechanisms.
| Trial number | Title | Status |
|---|---|---|
| NCT01391143 | Safety Study of MGA271 in Refractory Cancer | Completed |
| NCT02381314 | Safety Study of Enoblituzumab (MGA271) in Combination with Ipilimumab in Refractory Cancer | Completed |
| NCT02982941 | Enoblituzumab (MGA271) in Children with B7-H3-expressing Solid Tumors | Completed |
| NCT02923180 | Neoadjuvant Enoblituzumab (MGA271) in Men with Localized Intermediate and High-Risk Prostate Cancer | Active not recruiting |
| NCT04129320 | Enoblituzumab Plus MGA012 in Squamous Cell Carcinoma of the Head and Neck | Not yet recruiting |
| NCT02475213 | Safety Study of Enoblituzumab (MGA271) in Combination with Pembrolizumab or MGA012 in Refractory Cancer | Active not recruiting |
| NCT03729596 | MGC018 With or Without MGA012 in Advanced Solid Tumors | Recruiting |
| NCT02628535 | Safety Study of MGD009 in B7-H3-expressing Tumors | Terminated |
| NCT03406949 | MGD009/MGA012 Combination in Relapsed/Refractory Cancer | Active not recruiting |
| NCT01502917 | Convection-Enhanced Delivery of 124I-8H9 for Patients with Non-Progressive Diffuse Pontine Gliomas Previously Treated with External Beam Radiation Therapy | Recruiting |
| NCT01099644 | Intraperitoneal Radioimmunotherapy with 131I-8H9 for Patients with Desmoplastic Small Round Cell Tumors and Other Solid Tumors Involving the Peritoneum | Active not Recruiting |
| NCT00089245 | Radiolabeled Monoclonal Antibody Therapy in Treating Patients with Refractory, Recurrent, or Advanced CNS or Leptomeningeal Cancer | Active not recruiting |
| NCT04022213 | A Study of the Drug I131-Omburtamab in People with Desmoplastic Small Round Cell Tumors and Other Solid Tumors in the Peritoneum | Recruiting |
| NCT04167618 | 177Lu-DTPA-Omburtamab Radioimmunotherapy for Recurrent or Refractory Medulloblastoma | Not yet recruiting |
| NCT04145622 | Study of DS-7300a in Participants with Advanced Solid Malignant Tumors | Recruiting |
| NCT04185038 | Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors | Recruiting |
| NCT04077866 | B7-H3 CAR-T for Recurrent or Refractory Glioblastoma | Recruiting |
| NCT04432649 | Targeting CD276 (B7-H3) Positive Solid Tumors by 4SCAR-276 | Recruiting |
| NCT04385173 | Pilot Study of B7-H3 CAR-T in Treating Patients with Recurrent and Refractory Glioblastoma | Recruiting |
| NCT04483778 | B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults | Recruiting |
| NCT04315246 | 177Lu-DTPA-Omburtamab Radioimmunotherapy for Leptomeningeal Metastasis from Solid Tumors | Not yet recruiting |